| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8827541 | Transplantation Proceedings | 2017 | 10 Pages |
Abstract
Novel efficacy endpoints as required by the European Medicines Agency and US Food and Drug Administration demonstrate noninferiority of prolonged-release versus immediate-release tacrolimus. Significantly more patients treated with prolonged-release tacrolimus versus immediate-release tacrolimus achieved trough levels of 5 to 15 ng/mL early after transplantation. ClinicalTrials.govNCT00189839; NCT00717470.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
B.K. Krämer, L. Albano, B. Banas, B. Charpentier, L. Bäckman, H. Jr., F. Lehner, G.A. Mondragón-RamÃrez, M. Glyda, E. Cassuto-Viguier, O. Viklický, G. Mourad, P. Rigotti, S. Schleibner, N. Kamar,